Short term statin treatment and endothelial dysfunction due to ischemia and reperfusion injury

Short term statin treatment and endothelial dysfunction due to ischemia and reperfusion injury - Statins-IRI-FMD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33420

Enrollment

Registered

2009-08-07

Start date

2009-10-05

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemia and reperfusion injury myocardial infarction

Interventions

Treatment with either rosuvastatin 20 mg, atorvastatin 80mg or placebo during either 3 or 7 days

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age 18-50 - Written informed consent

Exclusion criteria

Exclusion criteria: - Smoking - History of any cardiovascular disease - Hypertension (in supine position: systole >140 mmHg, diastole >90 mmHg) - Diabetes Mellitus (fasting glucose >7.0 mmol/L or random glucose >11.0 mmol/L) - Hyperlipidemia (fasting total cholesterol >5.5 mmol/L or random cholesterol >6.5 mmol/L) - Alanine amino transferase >90 U/L - Creatine kinase >440 U/L - Raised rabdomyolysis risk o GFR

Design outcomes

Primary

Measure	Time frame
Difference in flow mediated dilation before and after 15 minutes ischemia.	—

Secondary

Measure	Time frame
ecto-5*-nucleotidase activity after rosuvastatin and atorvastatin treatment (3 day and 7 day)	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)